Azithromycin effect on helicobacter pylori eradication: double blind randomized clinical trial

Area of Science:

• Gastroenterology
• Infectious Diseases
• Pharmacology

Background:

• Helicobacter pylori infection is a significant global health concern.
• Quadruple therapy is a common treatment for H. pylori eradication.
• Optimizing treatment regimens for efficacy and tolerability is crucial.

Purpose of the Study:

• To compare the efficacy of one- and two-week quadruple therapy regimens containing azithromycin for H. pylori eradication.
• To evaluate the impact of different azithromycin dosages on eradication rates and side effects.

Main Methods:

• A randomized trial involving 84 H. pylori-infected patients.
• Three groups received varying durations and dosages of azithromycin-based quadruple therapy (AzOAB).
• Eradication was confirmed via urea breath test four weeks post-treatment.

Main Results:

• Eradication rates were 92% (2-week), 88.46% (1-week, 3g AzOAB), and 80% (1-week, 1.5g AzOAB).
• No significant difference in eradication rates was observed between the groups (P=0.44).
• The 1.5g AzOAB group reported significantly fewer side effects (0%) compared to the 6g AzOAB group (19.23%).

Conclusions:

• One-week quadruple therapy with 3g Azithromycin (AzOAB) appears favorable for H. pylori eradication.
• This regimen demonstrates comparable efficacy to longer durations with potentially fewer adverse events.
• Further research may support the 3g AzOAB regimen as a preferred option.